» Authors » Ana S Lukic

Ana S Lukic

Explore the profile of Ana S Lukic including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 221
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Matthews D, Kinney J, Ritter A, Andrews R, Toledano Strom E, Lukic A, et al.
Alzheimers Dement (N Y) . 2024 Jul; 10(3):e12490. PMID: 38988416
Introduction: The "A/T/N" (amyloid/tau/neurodegeneration) framework provides a biological basis for Alzheimer's disease (AD) diagnosis and can encompass additional changes such as inflammation ("I"). A spectrum of T/N/I imaging and plasma...
2.
Shuping J, Matthews D, Adamczuk K, Scott D, Rowe C, Kreisl W, et al.
Alzheimers Dement (N Y) . 2023 Mar; 9(1):e12372. PMID: 36873926
Background: The positron emission tomography (PET) radiotracer [F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs,...
3.
Matthews D, Lukic A, Andrews R, Wernick M, Strother S, Schmidt M
Alzheimers Dement (N Y) . 2022 Jul; 8(1):e12325. PMID: 35846158
Introduction: Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early-stage subjects do not worsen clinically during a clinical trial, and...
4.
Raikes A, Hernandez G, Matthews D, Lukic A, Law M, Shi Y, et al.
Alzheimers Dement (N Y) . 2022 Mar; 8(1):e12258. PMID: 35310526
Introduction: Allopregnanolone (ALLO), an endogenous neurosteroid, promoted neurogenesis and oligogenesis and restored cognitive function in animal models of Alzheimer's disease (AD). Based on these discovery research findings, we conducted a...
5.
Matthews D, Mao X, Dowd K, Tsakanikas D, Jiang C, Meuser C, et al.
Brain . 2021 Jun; 144(12):3742-3755. PMID: 34145880
Dysregulation of glutamatergic neural circuits has been implicated in a cycle of toxicity, believed among the neurobiological underpinning of Alzheimer's disease. Previously, we reported preclinical evidence that the glutamate modulator...
6.
Matthews D, Ritter A, Thomas R, Andrews R, Lukic A, Revta C, et al.
Alzheimers Dement (N Y) . 2021 Feb; 7(1):e12106. PMID: 33614888
Background: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor approved for Parkinson disease, in...
7.
Rafii M, Lukic A, Andrews R, Brewer J, Rissman R, Strother S, et al.
J Alzheimers Dis . 2017 Sep; 60(2):439-450. PMID: 28946567
Background: Adults with Down syndrome (DS) represent an enriched population for the development of Alzheimer's disease (AD), which could aid the study of therapeutic interventions, and in turn, could benefit...
8.
Matthews D, Lukic A, Andrews R, Marendic B, Brewer J, Rissman R, et al.
Alzheimers Dement (N Y) . 2017 Jun; 2(2):69-81. PMID: 28642933
Introduction: Down Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)-like amyloid plaques and tangles and a high incidence of dementia and could provide an enriched population to study AD-targeted...
9.
Roberts D, Yang Y, Lukic A, Wilensky J, Wernick M
Ophthalmic Surg Lasers Imaging . 2012 Mar; 43(3):196-204. PMID: 22390965
Background And Objective: To investigate near infrared iris transillumination (NIRit) imaging as a new method to quantify pupil shape, size, and position because the imaging modality can uniquely provide simultaneous...
10.
Yourganov G, Chen X, Lukic A, Grady C, Small S, Wernick M, et al.
Neuroimage . 2010 Sep; 56(2):531-43. PMID: 20858546
Estimation of the intrinsic dimensionality of fMRI data is an important part of data analysis that helps to separate the signal of interest from noise. We have studied multiple methods...